Nasdaq · CIK 0001612042
ASND Ascendis Pharma A/S
Insider trading from SEC Form 4. Last filing 14 d ago. Close $229.23 on Oct 9, 2026, +17% from the 52-week low and -17% from the high.
Last 90 days
Net insider value
-$873k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$873k by 2 insiders
Insiders on file
3
with a Form 4 at this company
Price and insider trades, last year
ASNDOct 9, 2026 · close 229.23
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Ascendis Pharma A/S, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mads Bodenhoff SVP & PAO sell | $811k 3,000 shares | -100% | - | |
| 30Weak | Lars Holtug director sell | $62k 236 shares | -6% | - |
Transactions
The last 6 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 14, 2026 | Jean Jacques Bienaime director | DDisposition to issuer Warrantsderivative | -9,160 | - | - | 0 | 14 d ago |
| Apr 14, 2026 | Jean Jacques Bienaime director | AGrant or award Warrantsderivative | +9,160 | - | - | 9,160 | 14 d ago |
| Sep 8, 2026 | Mads Bodenhoff SVP & PAO | MOption exercise Ordinary Shares | +3,000 | $110.00 | $330k | 3,000 | 33 d ago |
| Sep 8, 2026 | Mads Bodenhoff SVP & PAO | SOpen-market sale Ordinary Shares | -3,000 | $270.19 | $811k | 0 | 33 d ago |
| Sep 8, 2026 | Mads Bodenhoff SVP & PAO | MOption exercise Warrantsderivative | -3,000 | $0.00 | $0 | 687 | 33 d ago |
| Sep 2, 2026 | Lars Holtug director | SOpen-market sale Ordinary Shares | -236 | $264.13 | $62k | 4,000 | 39 d ago |
Insiders
Everyone who has filed a Form 4 here.
- Jean Jacques Bienaimedirector
- Mads BodenhoffSVP & PAO
- Lars Holtugdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.